ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Portfolio Pulse from
ADC Therapeutics announced positive initial data from its LOTIS-7 clinical trial, showing that ZYNLONTA in combination with glofitamab is effective in treating relapsed/refractory diffuse large B-cell lymphoma, with a 94% overall response rate and 72% complete response rate. The treatment showed no dose-limiting toxicities or severe side effects.
December 11, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADC Therapeutics' positive trial results for ZYNLONTA in combination with glofitamab could boost investor confidence and potentially increase stock prices. The treatment showed high efficacy and safety in treating relapsed/refractory diffuse large B-cell lymphoma.
The positive clinical trial results are likely to enhance the perceived value of ADC Therapeutics' product pipeline, potentially leading to increased investor interest and a rise in stock prices. The high efficacy and safety profile of the treatment are significant factors in this potential impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100